BRIEF-Vanda and UCSF announce license agreement for CFTR activators and inhibitors
March 29 Vanda Pharmaceuticals Inc -
* Vanda and UCSF announce license agreement for CFTR activators and inhibitors
* Under terms of deal, vanda will pay UCSF an initial license fee of $1 million and will be responsible for all development costs
* In 2017 intends to complete technology transfer activities from UCSF,initiate ind enabling studies for several CFTR indications
* To acquire exclusive worldwide license from UCSF to develop, commercialize portfolio of cftr activators, inhibitors Source text for Eikon: Further company coverage: